Pharmafile Logo
Pharmafocus logo
Advanced Search

Astellas

Showing 15 posts of 103 posts found.

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager

January 2, 2024
Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage

Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …

News
Chemotherapy

EMA accepts Astellas’ MAA for Zolbetuximab

July 14, 2023
Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorisation application (MAA) for regulatory …

News
shaking-hands-gb7ac17374_1920

Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders

June 15, 2023
Research and Development Astellas, Cullgen, Oncology, protein degraders

Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have entered into a strategic research …

News
credit_-_daniel_leal-olivas-afp

Astellas receives positive CHMP opinion for symptomatic anaemia drug

June 28, 2021
Sales and Marketing Astellas, CKD, anaemia

Astellas and FibroGen have announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted …

News

New NICE recommendation for Astellas prostate cancer drug

June 8, 2021
Manufacturing and Production Astellas, NICE, prostate cancer

A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …

News
MHRA sign

Astellas prostate cancer drug gets third approval from MHRA

May 12, 2021
Research and Development Astellas, MHRA, cancer research, cancer treatment, pharma, pharma news, prostate cancer

The MHRA has approved Astellas Pharma’s XTANDI (enzalutamide) drug for the treatment of a third form of prostate cancer, making …

News

Japan approves Astellas and FibroGen’s Evrenzo for chronic kidney disease patients currently not receiving dialysis

November 27, 2020
Medical Communications, Sales and Marketing Astellas, Japan, fibrogen

Japan’s Ministry of Health, Labour and Welfare (MHLW) has passed approval for Astellas and FibroGen’s Evrenzo (roxadustat) in the treatment …

News

China approves Astellas’ Xtandi in non-metastatic castration-resistant prostate cancer

November 6, 2020
Medical Communications, Sales and Marketing Astellas, China, NMPA, Xtandi

China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …

News
191209-f-kq373-1096

Seattle Genetics and Astellas unveil positive results for Padcev-Keytruda treatment for bladder cancer

February 12, 2020
Research and Development Astellas, Cancer, Seattle Genentics, bladder, bladder cancer, keytruda, monotherapy

Seattle Genetics and Astellas reported positive results from their trials of Padcev plus Keytruda in treating bladder cancer. The data …

News

NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia

January 23, 2020
Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia

The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …

News

FDA approves Astellas injectable antifungal drug for newborns

January 13, 2020
Sales and Marketing Astellas, Atellas Pharma, FDA, fungal virsus

The FDA has approved the first antifungal drug to specifically treat invasive candidiasis in newborns. From Astellas, the new drug …

News

Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash

December 3, 2019
Manufacturing and Production, Sales and Marketing Astellas, Audentes, acquisition, neuromuscular disease, pharma

Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it …

News

European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia

October 28, 2019
Sales and Marketing Astellas, Xospata, leukaemia, pharma

Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …

News
japans_ministry_of_health_labour_and_welfare

Japan approves Astellas and FibroGen’s Evrenzo for anaemia in dialysis patients

September 23, 2019
Sales and Marketing Astellas, anaemia, fibrogen, pharma

Astellas Pharma and FibroGen have revealed that their collaborative drug Evrenzo (roxadustat) has secured marketing authorisation in Japan for the …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

June 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma

Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024